Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Literature DB >> 3457021

Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

L M Slater, P Sweet, M Stupecky, S Gupta.

Abstract

The development of drug resistance by tumor cells is a major obstacle to the cure of human malignancy. Cyclosporin A (CsA) completely reverses primary resistance to vincristine and cross resistance to daunorubicin in a pleiotropic drug-resistant subline of human T cell acute lymphatic leukemia. This subline is over 50-fold resistant to vincristine and fivefold resistant to daunorubicin. CsA has little effect on vincristine or daunorubicin activity in drug-sensitive parental leukemia and corrects daunorubicin resistance without altering cellular daunorubicin accumulation.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1986 PMID： 3457021 PMCID： PMC424510 DOI： 10.1172/JCI112450

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

15 in total

Review 1. Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts.

Authors: W T Beck
Journal: Cancer Treat Rep Date: 1983-10

2. Binding of cyclosporine by human lymphocytes and phospholipid vesicles.

Authors: S J LeGrue; A W Friedman; B D Kahan
Journal: J Immunol Date: 1983-08 Impact factor: 5.422

3. Distribution and concentration of cyclosporin in human blood.

Authors: K Atkinson; K Britton; J Biggs
Journal: J Clin Pathol Date: 1984-10 Impact factor: 3.411

4. Targeted blood levels of cyclosporin for cardiac transplantation.

Authors: B P Griffith; R L Hardesty; A Trento; A Lee; H T Bahnson
Journal: J Thorac Cardiovasc Surg Date: 1984-12 Impact factor: 5.209

5. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin.

Authors: T Tsuruo; H Iida; M Yamashiro; S Tsukagoshi; Y Sakurai
Journal: Biochem Pharmacol Date: 1982-10-01 Impact factor: 5.858

6. Calcium modifies the accumulation and retention of daunorubicin by Ehrlich ascites carcinoma.

Authors: S L Murray; E M Du Vall; L M Slater
Journal: Cancer Chemother Pharmacol Date: 1984 Impact factor: 3.333

7. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.

Authors: L M Slater; S L Murray; M W Wetzel; R M Wisdom; E M DuVall
Journal: J Clin Invest Date: 1982-11 Impact factor: 14.808

8. Increased content of calmodulin in human leukemia cells.

Authors: D Takemoto; C Jilka
Journal: Leuk Res Date: 1983 Impact factor: 3.156

9. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Authors: T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal: Cancer Res Date: 1981-05 Impact factor: 12.701

10. Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance.

Authors: L M Slater; S L Murray; M W Wetzel; P Sweet; M Stupecky
Journal: Cancer Chemother Pharmacol Date: 1986 Impact factor: 3.333

65 in total

1. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype.

Authors: P A te Boekhorst; J van Kapel; M Schoester; P Sonneveld
Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333

2. Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas.

Authors: W H Wilson; S E Bates; A Fojo; B A Chabner
Journal: J Cancer Res Clin Oncol Date: 1995 Impact factor: 4.553

3. Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.

Authors: K Osann; P Sweet; L M Slater
Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333

4. Functional expression of mouse Mdr1 in an outer membrane permeability mutant of Escherichia coli.

Authors: O Béjà; E Bibi
Journal: Proc Natl Acad Sci U S A Date: 1996-06-11 Impact factor: 11.205

5. Chemosensitisation of a drug-sensitive parental cell line by low-dose cyclosporin A.

Authors: P R Twentyman; K A Wright
Journal: Cancer Chemother Pharmacol Date: 1991 Impact factor: 3.333

6. P-glycoprotein-expressing tumor cells are resistant to anticancer drugs in human gastrointestinal cancer.

Authors: T Hotta; H Tanimura; M Iwahashi; M Tani; T Tsunoda; K Noguchi; S Mizobata; K Arii; H Terasawa; M Nakamori; H Yamaue
Journal: Surg Today Date: 1999 Impact factor: 2.549

7. Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.

Authors: K Nooter; R Oostrum; R Jonker; H van Dekken; W Stokdijk; G van den Engh
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

8. Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.

Authors: S Gupta; J Kim; S Gollapudi
Journal: J Clin Invest Date: 1991-04 Impact factor: 14.808

9. Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice.

Authors: J J Schindler; R P Warren; S D Allen; M K Jackson
Journal: Antimicrob Agents Chemother Date: 1993-12 Impact factor: 5.191

10. Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia.

Authors: G Vreugdenhil; J M Raemaekers; B J van Dijke; B E de Pauw
Journal: Ann Hematol Date: 1993-09 Impact factor: 3.673